Antibody-Drug Conjugates

Informa Life Sciences’11th AnnualThe average costs of developing a bioSuperior is estimated to be 60% lessthan bringing a new product to market – find out what Medimmune, GSK andMacrogenics are doing to stay on top of this rapidly expanding areaRecombinant &Bispecific AntibodiesPart of:Wednesday 12 & Thursday 13 June 2013, Hotel Fira Palace, Barcelona, SpainAccelerate Product Development with Europe’s Most Industry-Driven Antibody ConferenceFocusing on Ground-Breaking Advances in Targeting, Engineering, Preclinical and ClinicalHear from 25+ speakers, 25+ case studies, 10+ hours of networking with 150+ attendeesSpecialRates forSMEs andAcademicsDr Luis BorgesScientific Director,Therapeutic Innovation UnitAmgen Inc, USADr Jijie GuSenior Principal ScientistAbbvie, USADr Dimiter S DimitrovSenior InvestigatorNational Institute of Health, USADr Mihriban TunaAssociate Vice President, DiscoveryF-Star Biotechnology Ltd, UKDr Eric SmithAssociate Director,Bispecific EngineeringRegeneron, USADr Ezio BonviniSenior Vice President, ResearchMacroGenics, Inc. USABrand New for 2013:4 New pre-conference symposium on target selection for recombinant and bispecific Antibodies4 Dedicated plenary session on building biosuperiority into current antibody formats4 Expanded session on engineering fusion Proteins and antibody fragments4 Explore the pros and cons of current bispecific antibody formats with 8+ case studiesKey Reasons Not to Miss Europe’s Favourite Antibody Conference!4 Benchmark your bispecific, ADC and mAb target selection strategies against Genentech, Medimmune &Bayer - full day pre-conference symposium4 Fast-track your fusion protein, antibody fragment and antibody mixtures development programmes withupdates from Symphogen, Randox Laboratories and NIH4 Optimise your products’ half-life & effector functions with critical insight from Macrogenics and Roche4 Pick a winning bispecific antibody format with advice from market leaders - Amgen, Macrogenics, F-Star,Genentech, Abbott, Glenmark Pharmaceuticals and many more…4 Accelerate your bispecific clinical development programmes with first-hand advice from Sanofi - Aventis,Regeneron and Affimed Therapeutics plus join our evening seminar on Moving Bispecific Antibodiesinto the ClinicChoice of 3 Industry-Led WorkshopsPlus hear from...4 Dr Tilman Schlothauer, Pharma Research and EarlyDevelopment (pRED), Roche, Germany4 Dr Muhammad Al-Hajj, Senior Director, Oncology R&D,GlaxoSmithKline, USA4 Dr Stanislas Blein, Deputy Director, AntibodyEngineering, Glenmark Pharmaceuticals, Switzerland4 Dr Justin Scheer, Scientist, Research and EarlyDevelopment, Genentech, USA4 Dr Andrew Nyborg, Senior Scientist, BiosuperiorEngineering, Medimmune, USA4 Dr John de Kruif, Chief Scientific Officer, Merus,Netherlands4 Dr Ercole Rao, Group Leader Antibody Engineering,Sanofi-Aventis, Germany4 Dr Ralph Minter, Fellow Technology, Antibody Discoveryand Protein Engineering, Medimmune, UK4 Dr Eugene Zhukovsky, Chief Scientific Officer, AffimedTherapeutics AG, SwitzerlandPre-Conference Symposium W: Tuesday 11th June 2013Target Selection for Bispecifics, RABs and ADCsSymposium leaders: Dr Heiner Apeler, Bayer Healthcare, Germany, Dr Nazzareno Dimasi, MedImmune, USA, Dr Rastislav Tamaskovic, University of Zurich,Switzerland, Dr Ralph Minter, MedImmune, UK, Dr Dimiter S Dimitrov, National Institute of Health, USA and Dr Kedan Lin, Genentech, USAEvening Seminar S: Wednesday 12th June 2013Moving Bispecific Antibodies into the ClinicSession speakers: Dr Luis Borges, Amgen Inc, USA, Dr Ercole Rao,Sanofi-Aventis, Germany, Dr Justin Scheer, Genentech, USA, Dr David Poon, Zymeworks,Canada and chaired by Dr Peter Bach, BioPharmaLogic LLC, UKFree EveningSeminar with4 day passNew for2013Post Conference Workshop X: Friday 14th June 2013Engineering Strategies to Reduce Immunogenicity for Antibodies, Fragments and ConjugatesLeader: David Bramhill, Founder, Bramhill Biological Consulting, LLC, USARegister online: www.informa-ls.com/antibodiesCongress Sponsors:Conference Exhibitor:New for2013